| Helen Te, | |
|
5841 S Maryland Ave, Chicago, IL 60637-1443 | |
| (888) 824-0200 | |
| Not Available |
| Full Name | Helen Te |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 32 Years |
| Location | 5841 S Maryland Ave, Chicago, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033272554 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 036092313 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The University Of Chicago Medical Center | Chicago, IL | Hospital |
| Community Hospital | Munster, IN | Hospital |
| St Mary Medical Center Inc | Hobart, IN | Hospital |
| Northshore University Healthsystem - Evanston Hospital | Evanston, IL | Hospital |
| Northwest Health - Porter | Valparaiso, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The University Of Chicago Medical Center | 7618880766 | 754 |
| University Of Chicago | 7719899426 | 1137 |
| University Of Chicago | 7719899426 | 1137 |
News Archive
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
Last week, at the fourth annual Clinical Trials in Emerging Economies conference, Margaret Ann Snowden, Director of Biostatistics and Data Management at Aeras Global TB Vaccine Foundation, and Daragh Ryan of Cmed Technology, presented a case study of the application of the latest in clinical data technology to a large Phase II clinical trial in South Africa. The presentation provided an update on how effective technology can be in promoting the development of affordable vaccine regimens for the prevention of tuberculosis (TB) worldwide.
Dyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
A pioneering study has found Australian parents who turned to medicinal cannabis to treat children with epilepsy overwhelmingly (75 percent) considered the extracts as "effective". Contrary to parental expectations, extracts generally contained low doses of cannabidiol - commonly considered to be a key therapeutic element and that has been successfully used in recent clinical trials to treat epilepsy.
› Verified 6 days ago
| Entity Name | University Of Chicago |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821048786 PECOS PAC ID: 7719899426 Enrollment ID: O20031103000094 |
News Archive
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
Last week, at the fourth annual Clinical Trials in Emerging Economies conference, Margaret Ann Snowden, Director of Biostatistics and Data Management at Aeras Global TB Vaccine Foundation, and Daragh Ryan of Cmed Technology, presented a case study of the application of the latest in clinical data technology to a large Phase II clinical trial in South Africa. The presentation provided an update on how effective technology can be in promoting the development of affordable vaccine regimens for the prevention of tuberculosis (TB) worldwide.
Dyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
A pioneering study has found Australian parents who turned to medicinal cannabis to treat children with epilepsy overwhelmingly (75 percent) considered the extracts as "effective". Contrary to parental expectations, extracts generally contained low doses of cannabidiol - commonly considered to be a key therapeutic element and that has been successfully used in recent clinical trials to treat epilepsy.
› Verified 6 days ago
| Entity Name | The University Of Chicago Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033218128 PECOS PAC ID: 7618880766 Enrollment ID: O20031106000203 |
News Archive
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
Last week, at the fourth annual Clinical Trials in Emerging Economies conference, Margaret Ann Snowden, Director of Biostatistics and Data Management at Aeras Global TB Vaccine Foundation, and Daragh Ryan of Cmed Technology, presented a case study of the application of the latest in clinical data technology to a large Phase II clinical trial in South Africa. The presentation provided an update on how effective technology can be in promoting the development of affordable vaccine regimens for the prevention of tuberculosis (TB) worldwide.
Dyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
A pioneering study has found Australian parents who turned to medicinal cannabis to treat children with epilepsy overwhelmingly (75 percent) considered the extracts as "effective". Contrary to parental expectations, extracts generally contained low doses of cannabidiol - commonly considered to be a key therapeutic element and that has been successfully used in recent clinical trials to treat epilepsy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Helen Te, 150 Harvester Dr, Suite 300, Burr Ridge, IL 60527-5919 Ph: () - | Helen Te, 5841 S Maryland Ave, Chicago, IL 60637-1443 Ph: (888) 824-0200 |
News Archive
ImmuPharma PLC the specialist discovery and development pharmaceutical company is pleased to announce today the final results from a Phase IIb trial of LUPUZOR™ in active patients with Systemic Lupus Erythematosus (SLE). Lupuzor™ administered at 200 mcg once-a-month for 3 months plus standard of care achieved a clinically significant improvement in patient response rate as measured by the combined score compared to placebo plus standard of care.
Last week, at the fourth annual Clinical Trials in Emerging Economies conference, Margaret Ann Snowden, Director of Biostatistics and Data Management at Aeras Global TB Vaccine Foundation, and Daragh Ryan of Cmed Technology, presented a case study of the application of the latest in clinical data technology to a large Phase II clinical trial in South Africa. The presentation provided an update on how effective technology can be in promoting the development of affordable vaccine regimens for the prevention of tuberculosis (TB) worldwide.
Dyax Corp. today announced that it has launched its newly enhanced product website, www.KALBITOR.com, featuring its comprehensive financial assistance program. KALBITOR (ecallantide) is approved for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.
A pioneering study has found Australian parents who turned to medicinal cannabis to treat children with epilepsy overwhelmingly (75 percent) considered the extracts as "effective". Contrary to parental expectations, extracts generally contained low doses of cannabidiol - commonly considered to be a key therapeutic element and that has been successfully used in recent clinical trials to treat epilepsy.
› Verified 6 days ago
Dr. Sorin C Danciu, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 3134 N Clark St, Chicago, IL 60657 Phone: 773-880-9722 | |
Anoopa A. Koshy, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 259 E Erie St Ste 2200, Chicago, IL 60611 Phone: 312-926-6000 | |
William Edmond Gerardi, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 3730 N Lake Shore Dr, Apartment 2a, Chicago, IL 60613 Phone: 773-244-3060 | |
Suparna Dutta, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1700 W Van Buren St, Suite 500, Chicago, IL 60612 Phone: 312-942-4200 Fax: 312-942-3568 | |
Alexandra Dumitrescu, Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5841 S Maryland Ave, Chicago, IL 60637 Phone: 888-824-0200 | |
Dr. Mitesh Mahesh Kabadi, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St Ste 1159, Chicago, IL 60612 Phone: 312-942-5020 | |
Dr. Marta Batus, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1725 W Harrison St, Suite 809, Chicago, IL 60612 Phone: 312-563-2487 Fax: 312-942-3192 |